trending Market Intelligence /marketintelligence/en/news-insights/trending/zf3o4fphiimcmqqg2a3oza2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

CEL-SCI raises over $3.7M; ability to continue still in doubt

Street Talk Episode 41 - How to Win the Funding Battle, Use Fintech to Play Offense

Forward Spark Spreads Suggest Rising Profitability Of US Renewables As Sector Matures

MA Activity The Big Story In Mature Online Video Platform Market

Martina Cheung Backs The Quality Program


CEL-SCI raises over $3.7M; ability to continue still in doubt

CEL-SCI Corp. raised over $3.7 million in a public offering, though concerns over its ability to continue business remain.

The company warned in its Form 10-K filed last week that recurring losses from operations and future liquidity needs raised "substantial doubt" about its ability to continue as a going concern unless it attracts additional capital.

However, despite the public offering, the company said it would not retract its previous statement.

CEL-SCI's lead cancer treatment, Multikine, is being studied in a phase 3 clinical trial involving patients with head and neck cancer.